Both a GHRH antagonist (MIA-690) and a GHRH agonist (MR-409) reduced inflammation, tissue damage, and pain in a mouse model of colitis, with the antagonist showing stronger anti-inflammatory effects linked to lower IGF-1 levels.
6+ inflammatory markers reducedMIA-690 significantly lowered PGE2, 8-iso-PGF2α, serotonin, TNF-α, IL-6, and iNOS expression in colitis-affected colon tissue, alongside reducing serum IGF-1.
What the researchers found
Both GHRH analogs — the antagonist MIA-690 and the agonist MR-409 — attenuated DSS-induced colitis in mice, improving clinical symptoms and reducing histopathological damage.
In ex vivo colon tissue, both peptides inhibited production of pro-inflammatory and oxidative markers triggered by bacterial toxin (LPS). In live mice, both reduced pain responses in hot plate and formalin tests and decreased sensitivity to inflammatory stimuli.
MIA-690 showed superior efficacy compared to MR-409, more strongly inhibiting prostaglandin E2, 8-iso-PGF2α, serotonin, TNF-α, IL-6, and nitric oxide synthase gene expression in colitis-affected colon tissue. MIA-690 also uniquely decreased serum IGF-1 levels in colitis mice, which may explain its stronger anti-inflammatory and antioxidant activity.
Why it matters
Current treatments for inflammatory bowel disease often have significant side effects and don't work for all patients. GHRH analogs represent a completely different therapeutic approach — targeting hormonal pathways rather than the immune system directly. The finding that both an agonist and antagonist of the same hormone receptor can reduce gut inflammation suggests a complex regulatory mechanism that could open new treatment avenues.
The numbers in context
MIA-690 reduced PGE2, 8-iso-PGF2α, 5-HT, TNF-α, IL-6, iNOS, and serum IGF-1; both analogs reduced pain and clinical symptoms; MIA-690 showed higher efficacy than MR-409
How the study worked
Researchers used both ex vivo and in vivo approaches. Isolated mouse colon specimens were exposed to bacterial lipopolysaccharide (LPS) to trigger inflammation, then treated with MIA-690 or MR-409. In live male mice, colitis was induced using dextran sodium sulfate (DSS) in drinking water. Peptides were administered subcutaneously. Pain sensitivity was assessed using hot plate and formalin tests. The team measured clinical colitis symptoms, histopathological tissue damage, inflammatory markers (PGE2, TNF-α, IL-6, iNOS), oxidative stress markers (8-iso-PGF2α), serotonin levels, and serum IGF-1.
Who was studied
Male mice with DSS-induced colitis treated with GHRH antagonist MIA-690, GHRH agonist MR-409, or vehicle
What this study cannot tell us
This is an animal study using a chemical model of colitis (DSS), which does not fully replicate the complexity of human inflammatory bowel disease. The study was short-term, so long-term effects and safety are unknown. Specific dosages and group sizes are not reported in the abstract. There was no comparison to standard colitis treatments like aminosalicylates or biologics, making it hard to judge relative effectiveness.
How to read the evidence
This is a preliminary animal study using a chemically induced colitis model in mice. While the results are promising and consistent across multiple endpoints, animal models do not reliably predict human outcomes, and key details like sample sizes are not reported. Significant further research including human trials would be needed.
When this study was published
Published in 2021, this is a relatively recent study. GHRH analogs remain an active area of research, and follow-up studies may have since expanded on these findings.
The bigger picture
Inflammatory bowel disease affects millions globally, and the search for better treatments with fewer side effects continues. This study adds to growing evidence that peptide hormones involved in growth and metabolism also play important roles in regulating inflammation. If GHRH analogs prove effective in humans, they could complement or offer alternatives to current immunosuppressive therapies for conditions like ulcerative colitis and Crohn's disease.
Questions still open
- Why do both a GHRH agonist and antagonist produce anti-inflammatory effects — does this suggest the mechanism is independent of classical GHRH receptor signaling?
- Would GHRH analogs be effective in other forms of inflammatory bowel disease beyond chemically induced colitis?
- Could the IGF-1 lowering effect of MIA-690 have unintended consequences with long-term use?
Common questions
How can both a GHRH blocker and activator reduce inflammation?
Could GHRH peptides become a treatment for inflammatory bowel disease in humans?
Read the original research
Protective effects of growth hormone-releasing hormone analogs in DSS-induced colitis in mice.
Scientific reports, 11(1), 2530
Citation
Recinella, Lucia; Chiavaroli, Annalisa; Di Valerio, Valentina; Veschi, Serena; Orlando, Giustino; Ferrante, Claudio; Gesmundo, Iacopo; Granata, Riccarda; Cai, Renzhi; Sha, Wei; Schally, Andrew V; Lattanzio, Rossano; Brunetti, Luigi; Leone, Sheila. (2021). Protective effects of growth hormone-releasing hormone analogs in DSS-induced colitis in mice.. Scientific reports, 11(1), 2530. https://doi.org/10.1038/s41598-021-81778-4